Cardiology Policy

Glenfield Hospital’s Nurse-Performed TAVI Uproar

Glenfield Hospital Cardiology – a leading NHS heart center just outside Leicester in the UK – set cardiology channels ablaze earlier this week with a since-deleted celebratory tweet announcing that one of its advanced nurse practitioners performed a whole TAVI procedure (aka TAVR in the U.S.) as the first operator.

While Glenfield Cardiology proclaimed it a “momentous day for Glenfield, UHL and the whole world,” most of CardioTwitter saw it quite differently, highlighted by two prominent Twitter threads that combined to accumulate over 1.6M views, 575 retweets, and 2,200 likes.

CardioTwitter’s many NP-led TAVI/TAVR critics…

  • Were in disbelieve that this actually happened
  • Disagreed with choosing TAVI, given its complexity and specialization
  • Reminded that being a TAVI operator also includes handling planning, patient management, and complications
  • Questioned why cardiologists must go through years of training and costly boards to perform the same procedure
  • Criticized the impact decisions like this have on physician training
  • Worried that this is a turning point in NP cardiology scope creep

Although massively outnumbered, CardioTwitter’s handful of NP-led TAVI/TAVR defenders…

  • Noted that this NP was likely talented and Glenfield is a solid institution (even critics agreed with these points)
  • Reminded that NPs are already expanding their role in the cath lab and other areas of cardiology
  • Suggested that TAVI is a team effort, and an NP with the right capabilities and training could be the first operator if they worked alongside a physician

The threads also revealed widespread confusion about Glenfield and the NHS’s motives…

  • Few seemed to agree with Glenfield’s suggestion that NPs would improve TAVI access
  • Some suggested that this is part of a larger conspiracy to shift more procedures to “mid-levels,” prioritizing costs over patient care
  • Some theorized that health systems are shifting procedures to NPs to prepare for future physician shortages 
  • Others argued that this “was done purely for clout,” which seems more problematic than any of the above theories

The Takeaway

Regardless where you stand on the role of NPs in cardiology, these Twitter responses make it very clear that most cardiologists aren’t ready for NPs to lead complex procedures and aren’t comfortable with the potential motivations behind this decision. Even if Glenfield’s first NP-led TAVI seems like an isolated event, these Twitter treads provide a helpful (and concerning) glimpse into what to expect if NPs’ scope continues to expand to more advanced areas of cardiology.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions June 23, 2025

Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!